EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
Abstract
Authors
F Farhane V Bhan F Clift M Baharnoori K Thomas BP Patel F Blanchette NE Adlard U Vudumula K Gudala N Dutta D Grima S Mouallif